Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Pembrolizumab Vorinostat

Related Conditions

Often studied with 10 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT04357873Phase 2Completed

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

Showing all 1 trials

Research Network

Common Treatments

  • Pembrolizumab Vorinostat1

Active Sponsors

  • Merck Sharp & Dohme LLC1
  • UNICANCER1
  • Fondation ARC1
  • ERA-NET1

Top Investigators

Related Conditions

  • Anal Cancer1
  • Cervix Cancer1
  • Squamous Cell Lung Cancer1
  • Squamous Cell Carcinoma Of Cervix1
  • Squamous Cell Carcinoma Of Anus1

Activity Timeline